Literature DB >> 33452661

Incidence and risk factors of venous thromboembolism in ANCA-associated vasculitis: a metaanalysis and metaregression.

Panupong Hansrivijit1, Angkawipa Trongtorsak2, Kinjal P Gadhiya3, Kriti Lnu3, Christina T Dimech3, Charat Thongprayoon4, Wisit Cheungpasitporn4, Stewart H Lecker5.   

Abstract

The incidence of venous thromboembolism (VTE) in ANCA-associated vasculitis patients varies in different populations. Moreover, the risk factors for VTE in these patients are poorly described due to the small number of events. Ovid MEDLINE, EMBASE, and the Cochrane Library were searched for eligible articles. The inclusion criteria included observational studies that enrolled patients age ≥ 18 years diagnosed with ANCA-associated vasculitis. The incidence of VTE is the outcome of interest. Of 1362 citations, a total of 21 studies (n = 4422) dated from 2006 to 2019 were included in the systematic review. The mean age was 54.2 ± 4.0 years. Most were male (52.0%) and Caucasian (80.9%). With a mean follow-up duration of 5.2 ± 2.8 years, the pooled incidence of VTE in ANCA-associated vasculitis patients was 12.4% (95% CI, 8.8-17.2). Of these, 63.4% (95% CI, 57.3-69.1) had deep vein thrombosis and 26.3% (95% CI, 17.6-37.4) had pulmonary embolism. Recurrent VTE occurred in 10.0% (95% CI, 5.2-18.6). From the metaregression adjusted for age, sex, and ethnicity; positive MPO-ANCA, increasing Birmingham Vasculitis Activity Score at time of vasculitis diagnosis, and presence of renal involvement were positively associated with increased VTE events. Positive PR3-ANCA profile was inversely associated with increased VTE events. Increasing follow-up duration was not associated with increased VTE events. VTE in ANCA-associated vasculitis is common. Positive MPO-ANCA, increasing vasculitis activity, and presence of renal involvement were significant risk factors for VTE while positive PR3-ANCA was inversely associated with increased VTE. Key Points • Venous thromboembolism (VTE) is common in ANCA-associated vasculitis with a pooled incidence of 12.4% • Deep vein thrombosis accounts for two-third of total VTE cases • Positive MPO-ANCA profile, higher disease activity at ANCA-associated vasculitis diagnosis, and renal involvement are risk factors for VTE • Positive PR3-ANCA profile is protective factor for VTE.

Entities:  

Keywords:  ANCA; Antineutrophil cytoplasmic antibodies; Thrombosis; VTE; Vasculitis; Venous thromboembolism

Mesh:

Substances:

Year:  2021        PMID: 33452661     DOI: 10.1007/s10067-021-05589-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  33 in total

1.  Venous thromboembolic events in systemic vasculitis.

Authors:  Pavel Novikov; Egor Makarov; Sergey Moiseev; Alexey Meshkov; Leonid Strizhakov
Journal:  Ann Rheum Dis       Date:  2014-11-07       Impact factor: 19.103

2.  Promoting continence--continence advice.

Authors:  A Turner
Journal:  Geriatr Nurs Home Care       Date:  1989-03

Review 3.  Overview of venous thromboembolism.

Authors:  Haley M Phillippe
Journal:  Am J Manag Care       Date:  2017-12       Impact factor: 2.229

Review 4.  Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

Authors:  D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

Review 5.  Clinical and laboratory characteristics of 19 patients with Churg-Strauss syndrome from a single South Australian centre.

Authors:  A F Whyte; W B Smith; S N Sinkar; F E Kette; P Hissaria
Journal:  Intern Med J       Date:  2013-07       Impact factor: 2.048

6.  The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: A general population-based study.

Authors:  J Antonio Aviña-Zubieta; Kateryna Vostretsova; Mary A De Vera; Eric C Sayre; Hyon K Choi
Journal:  Semin Arthritis Rheum       Date:  2015-05-19       Impact factor: 5.532

7.  Plasmapheresis rescue therapy in progressive systemic ANCA-associated vasculitis: single-center results of stepwise escalation of immunosuppression.

Authors:  Anoek A E de Joode; Jan S F Sanders; W Martin Smid; Coen A Stegeman
Journal:  J Clin Apher       Date:  2014-02-04       Impact factor: 2.821

8.  High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients.

Authors:  Y Allenbach; R Seror; C Pagnoux; L Teixeira; P Guilpain; L Guillevin
Journal:  Ann Rheum Dis       Date:  2008-11-17       Impact factor: 19.103

Review 9.  The antineutrophil cytoplasmic antibody-associated vasculitides.

Authors:  Philip Seo; John H Stone
Journal:  Am J Med       Date:  2004-07-01       Impact factor: 4.965

10.  Coagulation and fibrinolysis index profile in patients with ANCA-associated vasculitis.

Authors:  Tian-Tian Ma; Yi-Min Huang; Chen Wang; Ming-Hui Zhao; Min Chen
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

View more
  1 in total

Review 1.  Mechanisms of thrombosis in ANCA-associated vasculitis.

Authors:  Durga Prasanna Misra; Koshy Nithin Thomas; Armen Yuri Gasparyan; Olena Zimba
Journal:  Clin Rheumatol       Date:  2021-06-09       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.